Leaving a gift in your Will is an incredible act, and a lasting way to support our work and research.

The survival of children diagnosed with cancer has dramatically improved over the last 10 years. However, for children diagnosed with diffuse intrinsic pontine glioma (DIPG), a form of diffuse midline glioma (DMG), there are no effective pharmacological or immunological treatments available; median survival remains less than 10 months. In Australia, 101 children under the age of 15 die from cancer each year. Although incidence is seemingly rare, DMG including DIPG are responsible for 25% of these deaths.

Gifts can take many forms:

  • the residue or percentage of the Estate;
  • a specific amount of money;
  • a life insurance or superannuation policy;
  • assets such as shares, property, works of art or jewellery;
  • an investment in perpetuity.

Leaving a bequests in a Will is a wonderful way to positively impact the lives of children diagnosed with cancer.

Dr Phoebe Dun Chairperson

If you have any questions or would like to find out more about leaving a bequest in your Will to RUN DIPG, please request an information pack or contact Dr Phoebe Dun on XXXXXX or email XXXX


RUN DIPG will be recognised as a go-to source of DIPG/DMG information for patients, families and communities alike.

We will contribute to the cost of improving the treatment of DIPG/DMG via the funding of scientific and clinical research as well as equipment to increase the clinical relevance of research. RUN DIPG’s advocacy, collaboration and financial support will make a documented contribution towards improved outcomes for DIPG/DMG patients.


Josephine Laura Dun was diagnosed with DIPG in February 2018, then just two years of age. The daughter of local GP, Dr Phoebe Hindley (Dun), and of Biomedical Scientist, Dr Matt Dun – as well as an adored big sister to George (and soon Harriet), the family found themselves in a tragic, but unique position to make a difference for all patients and families impacted by DIPG.

Matt and Phoebe, together with Josie’s treating oncologists set out to understand everything they could about DIPG/DMG. It soon became clear to Matt as a cancer researcher that very little was known about DIPG/DMG; the mechanisms controlling the tumour’s growth and its ability to avoid normal cell death processes are poorly understood. To address this, Matt’s own cancer research group at the University of Newcastle and Hunter Medical Research Institute (previously leukaemia-focused) set about creating their own program of DIPG/DMG research. Worldwide, the scientific community shared their DIPG/DMG-specific research protocols and even assisted in training Dr Dun’s staff in the techniques required to model DIPG/DMG in a laboratory.

Finding himself somewhat numbed by Josephine’s fatal diagnosis; Matt found focus through running – it was here that he would attempt to piece together the next steps in the DIPG/DMG research puzzle, and to plan the next steps in Josie’s fight against DIPG. Realising that such a rare cancer would never secure the attention (and by proxy, the funding) required to make headway in DIPG/DMG research, he called on the community around them. Internationally, family, friends, colleagues and even other families affected by DIPG began the process of bringing DIPG/DMG to the attention of the world through running, rugby, hiking, cycling, paddling, dancing and swimming in the name of DIPG awareness. With community-based sports events so readily accessible, and providing such a far-reaching platform for advocacy for DIPG/DMG research and awareness, Matt, Phoebe and Josie, together with their closest and most passionate supporters, formalised their efforts to create the charity ‘RUN DIPG’… because you know, ‘it’s tricky’ this brain tumour stuff!

RUN DIPG Ltd was created as a public company and registered with the Australian Charities and Not-for-profits Commission on 5 March 2019. We obtained tax-deductibility registration from the Australian Tax Office in May 2019.

Josephine passed away in December 2019, 22 months post-diagnosis, forever four years old. Unfortunately, most patients do not survive nearly as long; median survival is just 9-10 months post-DIPG diagnosis. In light of this, RUN DIPG is committed to raising awareness, advocating for improved clinical outcomes and financially supporting DIPG/DMG research to reduce the suffering of DIPG patients, their families and the communities supporting those affected by this, the most devastating childhood cancer.


Together we make all the difference


PO Box 110
St Leonards NSW 1590


E | hello@rundipg.org


Go to Top